JanOne Inc. (JAN)

NASDAQ: JAN · IEX Real-Time Price · USD
2.630
+0.120 (4.78%)
Mar 28, 2024, 3:59 PM EDT - Market closed

Company Description

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction.

It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain.

It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs.

The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019.

JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

JanOne Inc.
JanOne logo
Country United States
Founded 1976
Industry Waste Management
Sector Industrials
Employees 199
CEO Tony Isaac

Contact Details

Address:
325 E. Warm Springs Road, Suite 102
Las Vegas, Nevada 89119
United States
Phone 702-997-5968
Website janone.com

Stock Details

Ticker Symbol JAN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000862861
CUSIP Number 47089W104
ISIN Number US47089W1045
Employer ID 41-1454591
SIC Code 2834

Key Executives

Name Position
Tony Isaac President, Chief Executive Officer, Corporate Secretary and Director
Virland A. Johnson CPA Chief Financial Officer
Dr. Tony Giordano Ph.D. Chief Scientific Officer
Cyndy L. Janzig Director of Human Resources
Dr. Douglas Flanagan Chief Formulation Advisor

Latest SEC Filings

Date Type Title
Mar 15, 2024 8-K Current Report
Feb 28, 2024 8-K Current Report
Feb 9, 2024 8-K/A [Amend] Current report
Feb 8, 2024 8-K Current Report
Jan 12, 2024 8-K Current Report
Nov 14, 2023 10-Q Quarterly Report
Oct 11, 2023 8-K Current Report
Sep 22, 2023 8-K/A [Amend] Current report
Sep 15, 2023 8-K Current Report
Aug 28, 2023 DEF 14A Other definitive proxy statements